Loss of p53 accelerates neointimal lesions of vein bypass grafts in mice.
The transcription factor p53 is essentially involved in regulation of cell death and proliferation. Recently, we have established a mouse model for vein graft arteriosclerosis by grafting autologous jugular veins or vena cava to carotid arteries. Using this model, we studied the role of p53 in the development of vein graft arteriosclerosis in p53(-/-) mice. Four weeks after grafting, neointimal hyperplasia of vein grafts in p53(-/-) mice was increased 2-fold compared with that of wild-type controls. Cell component analysis revealed that neointimal lesions in p53(-/-) mice consisted mainly of alpha-actin positive smooth muscle cells (SMCs), whereas the majority of cells in wild-type mice were MAC-1 (CD11b/18)-positive at 4 weeks. Importantly, SMC apoptosis as determined by TUNEL assay was significantly reduced in p53(-/-) vein grafts. TUNEL positive cells in wild-type vein grafts markedly increased from 0.5% to 6.4% of total cells 4 weeks postoperatively, but remained virtually unchanged in p53(-/-) grafts (0.8%). Immunofluorescence analysis revealed that increased p53 expression in neointimal SMCs of wild-type, but not p53(-/-), mice coincided with oxidative DNA damage in vein grafts. Interestingly, SMCs of p53(-/-) mice showed increased apoptosis in response to TNFalpha and decreased apoptosis in response to sodium nitroprusside. Additionally, p53-deficient SMCs showed a higher rate of proliferation and migration and expressed higher levels of matrix metalloproteinases. Thus, p53 deficiency accelerates neointima formation by facilitating SMC proliferation as well as abrogating cell apoptosis.
Mayr
Ursula
U
Institute for Pathophysiology, University of Innsbruck, Austria.
Mayr
Manuel
M
Li
Chaohong
C
Wernig
Florian
F
Dietrich
Hermann
H
Hu
Yanhua
Y
Xu
Qingbo
Q
D000199:Actins / Q000096:biosynthesis; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002339:Carotid Arteries / Q000601:surgery; D002455:Cell Division / Q000235:genetics; D002465:Cell Movement / Q000235:genetics; D004249:DNA Damage / Q000235:genetics; D018450:Disease Progression; D020022:Genetic Predisposition to Disease; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D006579:Heterozygote; D020287:In Situ Nick-End Labeling; D007601:Jugular Veins / Q000378:metabolism / Q000473:pathology / Q000637:transplantation; D016177:Macrophage-1 Antigen / Q000096:biosynthesis; D051379:Mice; D018345:Mice, Knockout; D008817:Mice, Mutant Strains; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009599:Nitroprusside / Q000494:pharmacology; D010084:Oxidation-Reduction; D014182:Transplantation, Autologous / Q000009:adverse effects; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism; D014656:Vascular Surgical Procedures / Q000009:adverse effects; D014680:Veins / Q000378:metabolism / Q000473:pathology / Q000637:transplantation*
D000199:Actins; D016177:Macrophage-1 Antigen; D014409:Tumor Necrosis Factor-alpha; D016159:Tumor Suppressor Protein p53; D009599:Nitroprusside